Search the site Search

Healthcare Professionals

Share price: Latest: (SEK) High: (SEK)

About us
Science & Pipeline
Patient & Caregivers
Investors
News & Insights
- Press releases
- Latest From LinkedIn
Careers
Contact
- Offices & Locations
- Contact form

Home ▸ Investors Content ▸ Redeye interview with CEO after Q4 report 17 February 2022

Redeye interview with CEO after Q4 report 17 February 2022

February 17, 2022

View Redeye interview with CEO after Q4 report 17 February 2022

Share

We care for the rare

Rare Thyroid Therapeutics International is a wholly owned subsidiary of Egetis Therapeutics

Follow us on Go to Youtube Go to LinkedIn Go to Facebook Go to X

Useful links

About us
Science & Pipeline
Patient & Caregivers
Contact

More from us

News & Insights
Careers
Press releases

Investor

Investors
Reports & Presentations
The Share
IR-contact

© 2018-2026 Egetis Therapeutics. All rights reserved.

Privacy Notice
Cookie Settings
Cookie Policy
Sitemap

Skip to toolbar

About WordPress

Search

Home
About us
Science & Pipeline
Patient & Caregivers
Investors
News & Insights
- Press releases
- Latest From LinkedIn
Careers
Contact
- Offices & Locations
- Contact form

Healthcare Professionals

Subscribe

Be the first to hear about news from Egetis

You are leaving our website

You're about to visit an external website. Egetis Therapeutics is not responsible for its content.